Case report: Giant lymph node metastases: a new opportunity for cancer radioimmunotherapy?

Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considere...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1357601
Main Authors Bian, Yuan, Zhang, Zhenhua, Deng, Xiangyu, Wen, Qinglian, Li, Dan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite the significant progress made in radiotherapy and chemotherapy for the treatment of cervical cancer, patients with lymph node metastasis still have a poor prognosis. It is widely accepted that lymph node metastasis plays a crucial role in the spread of cancer to other organs and is considered an independent factor in predicting a poor prognosis. However, recent research suggests that the importance of lymph nodes in tumor therapy needs to be reevaluated, as preserving the integrity of lymph nodes before immunotherapy can enhance treatment effectiveness. In this report, we present two cases of advanced cervical cancer patients with giant metastatic lymph node lesions in the neck. These patients were effectively treated with a combination of local radiotherapy and immunotherapy after conventional chemoradiotherapy had failed. The combination therapy resulted in significant clinical improvements, with patient 1 achieving over 12 months of progression-free survival (PFS) and patient 2 maintaining sustained remission for an impressive 24 months. The combination of local radiotherapy and immunotherapy shows promise as a viable treatment option for cervical cancer patients with distant lymph node metastasis, and the giant lymph node metastases may play an important role in this process, which might provide a new opportunity for cancer radioimmunotherapy.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Christopher Hillyar, University of Oxford, United Kingdom
Edited by: Ming Yi, Zhejiang University, China
These authors have contributed equally to this work and share first authorship
Reviewed by: Tianye Li, Zhejiang University School of Medicine, China
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1357601